Literature DB >> 15285460

[ARIA--one airway, one disease: what links our research to the concept?].

Davor Plavec1.   

Abstract

ARIA (Allergic Rhinitis and its Impact on Asthma) is a public health initiative of the World Health Organization (WHO) based on the "one airway, one disease" concept. The trigger for the initiative was a growing evidence (from epidemiology, anatomy, pathophysiology, clinical diagnostics, therapy) of a pandemic increase in the prevalence of allergic disorders of the respiratory tract (allergic rhinitis and asthma), of the deficiency of primary and secondary preventive measures, and of incomplete therapeutic control over these conditions using current management strategies. Evidence gathered so far suggest a strong link between allergic rhinitis and asthma (anatomical and histological features, aetiology, similar pathophysiological mechanisms, related therapeutic results). Therefore, ARIA as a public health initiative aims at uniting the management of these, till now separated disorders. This review discusses the evidence on which the "one airway, one disease" concept and ARIA are based, including a contribution made by scientists from the Institute of Medical Research and Occupational Health, Zagreb, Croatia.

Entities:  

Mesh:

Year:  2004        PMID: 15285460

Source DB:  PubMed          Journal:  Arh Hig Rada Toksikol        ISSN: 0004-1254            Impact factor:   1.948


  1 in total

Review 1.  Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

Authors:  J Bousquet; A Bedbrook; W Czarlewski; G L Onorato; S Arnavielhe; D Laune; E Mathieu-Dupas; J Fonseca; E Costa; O Lourenço; M Morais-Almeida; A Todo-Bom; M Illario; E Menditto; G W Canonica; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; W J Fokkens; N H Chavannes; S Reitsma; A A Cruz; J da Silva; F S Serpa; D Larenas-Linnemann; J M Fuentes Perez; Y R Huerta-Villalobos; D Rivero-Yeverino; E Rodriguez-Zagal; A Valiulis; R Dubakiene; R Emuzyte; V Kvedariene; I Annesi-Maesano; H Blain; P Bonniaud; I Bosse; Y Dauvilliers; P Devillier; J F Fontaine; J L Pépin; N Pham-Thi; F Portejoie; R Picard; N Roche; C Rolland; P Schmidt-Grendelmeier; P Kuna; B Samolinski; J M Anto; V Cardona; J Mullol; H Pinnock; D Ryan; A Sheikh; S Walker; S Williams; S Becker; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P V Tomazic; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; T Vasankari; B Gemicioğlu; A Yorgancioglu; N G Papadopoulos; E P Prokopakis; I G Tsiligianni; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; M E Zernotti; I Kull; E Melén; M Wickman; C Bachert; P W Hellings; G Brusselle; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; L P Boulet; J Bouchard; D K Chu; H J Schünemann; M Sova; G De Vries; M van Eerd; I Agache; I J Ansotegui; M Bewick; T Casale; M Dykewick; M Ebisawa; R Murray; R Naclerio; Y Okamoto; D V Wallace
Journal:  Clin Transl Allergy       Date:  2019-03-11       Impact factor: 5.871

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.